FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Mammal patents



      
           
This page is updated frequently with new Mammal-related patent applications. Subscribe to the Mammal RSS feed to automatically get the update: related Mammal RSS feeds. RSS updates for this page: Mammal RSS RSS


Date/App# patent app List of recent Mammal-related patents
01/22/15
20150025616
 Method and  treating a carotid artery patent thumbnailnew patent Method and treating a carotid artery
One disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery (with or without blocking of blood flow through the external carotid artery), shunting blood from the internal carotid artery and treating the lesion in the carotid artery..
Silk Road Medical, Inc.
01/22/15
20150025407
 Devices and methods for generating an artificial exhalation profile patent thumbnailnew patent Devices and methods for generating an artificial exhalation profile
Methods and devices for creating an artificial exhalation profile, for example for use in the sampling of exhaled breath or air from the nasal cavity from a mammal, wherein said mammal exhales into a device comprising a flow channel, a pressure sensor, a flow sensor, a control unit, and means for creating an exhalation flow, wherein said means for creating an exhalation flow maintain an exhalation flow at one or more pre-determined flow rate (rates), within a predetermined interval, substantially independent of exhalation pressure.. .
Aerocrine Ab
01/22/15
20150025331
 System and method employing a thermocouple junction for monitoring of physiological parameters patent thumbnailnew patent System and method employing a thermocouple junction for monitoring of physiological parameters
Disclosed are systems and methods for enabling the acquisition of physiological parameters of a mammal or other specimen using thermo-mechanical responses (e.g., temperature, pressure and alternatively acceleration, pulse, position). In accordance with one example embodiment, a monitoring device for wired and/or wireless sensors is used to acquire a series of sensor signals that are attached to achieve the physiological measurements of a mammal vital signs is provided.
01/22/15
20150025313
 Intraluminal device delivery technique patent thumbnailnew patent Intraluminal device delivery technique
A technique for deploying an intraluminal device, such as a bariatric device, in a mammalian lumen, such as the gastrointestinal tract, includes positioning a visualization device through an orifice, such as a natural orifice, into the mammalian lumen. A deployment device having the intraluminal device mounted thereto is guided to the mammalian lumen.
Bfkw, Llc
01/22/15
20150025097
 Methods of reducing hair loss and/or facilitating hair growth and/or regrowth patent thumbnailnew patent Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
The present disclosure relates to methods of retarding hair loss or facilitating hair growth and/or regrowth. More specifically, the present disclosure relates to methods of using the disclosed compositions to increase the rate of terminal hair growth and/or regrowth in a mammal..
Mcneil-ppc, Inc.
01/22/15
20150025060
 Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor and related agents and their uses patent thumbnailnew patent Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor and related agents and their uses
The invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering such a composition to an afflicted target site.. .
01/22/15
20150024955
 Methods of identifying modulators of dephosphorylation of histone deacetylase patent thumbnailnew patent Methods of identifying modulators of dephosphorylation of histone deacetylase
The present invention relates to screening methods that make use of a histone deacetylase interacting with a myosin phosphatase for the identification of novel therapeutics useful for inhibiting or inducing apoptosis and for the treatment of pathological conditions, such as smooth muscle cell disorder, cardiac hypertrophy or asthma. Also disclosed are methods for inhibiting or inducing apoptosis and for treatment of a pathological condition by administering to a mammal a therapeutically effective amount of a compound that inhibits or increases the dephosphorylation of a histone deacetylase by a myosin phosphatase or inhibits or increases the binding of a histone deacetylase to a myosin phosphatase..
The J. David Gladstone Institutes
01/22/15
20150024431
 Thrombopoietic compounds patent thumbnailnew patent Thrombopoietic compounds
The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal..
Amgen Inc.
01/22/15
20150024420
 Extracellular and membrane-associated prostate cancer markers patent thumbnailnew patent Extracellular and membrane-associated prostate cancer markers
This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals.
Mayo Foundation For Medical Education And Research
01/22/15
20150024407
 T1r hetero-oligomeric taste receptors patent thumbnailnew patent T1r hetero-oligomeric taste receptors
Newly identified mammalian taste-cell-specific g protein-coupled receptors which function as hetero-oligomeric complexes in the sweet taste transduction pathway, and the genes and cdna encoding said receptors are described. Specifically, t1r g protein-coupled receptors active in sweet taste signaling as hetero-oligomeric complexes, and the genes and cdna encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors.
Senomyx, Inc.
01/22/15
20150024406
new patent

Increased aquaporin expression on cellular membrane to improve cryopreservation efficiency


A method of storing mammalian cells or tissue (e.g., liver cells or hepatocytes) for subsequent use comprises the steps of: (a) contacting the cells or tissue in vitro to a choleretic agent in an effective amount; (b) combining said cells or tissue with a cryopreservative; (c) freezing said cells or tissue, and then (d) storing said frozen cells or tissue in frozen form for subsequent use.. .
01/22/15
20150024066
new patent

Methods for preventing or treating excess weight using oxyntomodulin


Compositions and methods for use in the prevention or treatment of excess weight in a mammal have been developed. The compositions comprise oxyntomodulin which is shown to reduce food intake..
Imperial Innovations
01/22/15
20150024030
new patent

Protection against and treatment of ionizing radiation


Methods of preparing a proteoliposome comprise the step of contacting a liposome with an effective portion of ralbp1 to create a proteoliposome. Ralbp1 is effective for the protection and treatment of mammals and the environment against the accumulation of toxic compounds, and prevents accumulation of one or more toxic compounds, reduces the concentration of toxic compounds, and protects against further contamination with one or more toxic compounds.
University Of North Texas Health Science Center At Fort Worth
01/22/15
20150024009
new patent

Genetically modified organism for the production of lipids


The invention provides an isolated genetically modified non-mammalian organism, wherein the activity of acyl-coa:sterol acyltransferase/sterol o-acyltransferase (ec 2.3.1.26) and/or diacylglycerol acyltransferase/diacylglycerol o-acyltranferase (ec 2.3.1.20) and/or lecithin cholesterol acyl transferase/phospholipid: diacylglycerol acyltransferase (ec 2.3.1.158) and/or acyl coa-wax alcohol acyltransferase (ec 2.3.1.75) is reduced or abolished in comparison with a corresponding wildtype organism, methods of use of such an organism, shuttle vehicles for making such an organism and methods for producing such an organism.. .
Organobalance Gmbh
01/22/15
20150023993
new patent

Combination therapy using active immunotherapy


The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (mhc) class-i or class-ii. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof..
Immatics Biotechnologies Gmbh
01/22/15
20150023871
new patent

Compositions and methods for the diagnosis and treatment of tumor


The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.. .
Genentech, Inc.
01/15/15
20150020224

Non-human animals with modified immunoglobulin heavy chain sequences


Non-human animals, e.g., mammals, e.g., mice or rats, are provided comprising an immunoglobulin heavy chain locus that comprises a rearranged human immunoglobulin heavy chain variable region nucleotide sequence. The rearranged human immunoglobulin heavy chain variable region nucleotide sequence may be operably linked to a heavy or light chain constant region nucleic acid sequence.
Regeneron Pharmaceuticals, Inc.
01/15/15
20150018872

Use of reverse thermosensitive polymers to control biological fluid flow following a medical procedure


One aspect of the present invention relates to a method to control biological fluid flow at a site in a mammal by use of an in situ formed polymer plug. In certain embodiments, the present invention relates to a method to control bleeding following a catheterization procedure, a method to control leakage of cerebral spinal fluid following a lumbar puncture, a method to seal a fistula, or a method to control the flow of serous fluid after a lymphadenectomy.
Genzyme Corporation
01/15/15
20150018750

Cosmetic agent or skin regeneration promoter comprising a culture sup of non-human stem cells, and a introducing a protein


As the percentage of senior citizens increases at the present time, the purpose of the present invention is to provide a cosmetic which can maintain the skin in a healthy state by preventing damage to the skin that accompanies aging, more specifically, discoloration and wrinkling, is very safe, does not pose ethical problems, and can be supplied in a sufficient amount. The present invention provides a cosmetic that comprises as the main component a powder of the supernatant produced by culturing the bone marrow or dental pulp stem cells of a nonhuman mammal.
Japanic Corporation
01/15/15
20150018711

Endoscope including an torque generation component or torque delivery component disposed within an insertable portion of the endoscope and a surgical cutting assembly insertable within the endoscope


An endoscope for removing tissue at a surgical site includes an elongated tubular body insertable within a mammalian cavity of a patient. An instrument channel extends between a first opening at a distal end and a second opening at a proximal end of the tubular body and is sized and configured to receive a surgical cutting assembly that includes an aspiration channel configured to remove material entering the endoscope via a distal end of the surgical cutting assembly.
Interscope, Inc.
01/15/15
20150018710

Endoscope including an torque generation component or torque delivery component disposed within an insertable portion of the endoscope and a surgical cutting assembly insertable within the endoscope


An endoscope for removing tissue at a surgical site includes an elongated tubular body insertable within a mammalian cavity of a patient. An instrument channel extends between a first opening at a distal end and a second opening at a proximal end of the tubular body and is sized and configured to receive a surgical cutting assembly that includes an aspiration channel configured to remove material entering the endoscope via a distal end of the surgical cutting assembly.
Interscope, Inc.
01/15/15
20150018526

Cytotoxins comprising modified bouganin toxin for the treatment of cancer


The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human t cells as compared to the non-modified bouganin protein. The invention also provides t-cell epitope peptides of bouganin, and modified t-cell epitope peptides of bouganin which have a reduced propensity to activate human t cells as compared to the non-modified t-cell epitope peptide.
Merck Patent Gmbh
01/15/15
20150018410

Novel stat3 pathway inhibitors and cancer stem cell inhibitors


The present invention relates to a novel naphtho class of compounds as stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent stat3 pathway activity; to pharmaceutical compositions containing such compounds.. .
Boston Biomedical, Inc.
01/15/15
20150018405

Treatment of disease by modulation of sirt6


An aspect of an embodiment of the invention relates to providing treatment of disease, in particular age-related disease, through increasing or decreasing the activity of sirt6 protein. This may be accomplished through upregulation and downregulation of expression of sirt6 in mammals.
Bar-ilan University
01/15/15
20150018389

Method for treating parkinsons disease and other neurological diseases


A method for treating a central nervous system or peripheral nervous system dopaminergic deficit state in a mammalian organism in need of such treatment, said method comprising administering to said mammal an amount of thalidomide effective in the treatment of a dopaminergic deficit state and for a time sufficient to achieve a suitable blood level to treat said dopaminergic deficit state.. .
01/15/15
20150018288

Methods and compositions for preventing or treating ophthalmic conditions


The disclosure provides methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
Stealth Peptides International, Inc.
01/15/15
20150018273

Novel compositions and uses thereof


The present invention provides a composition for stimulating hair growth in a mammal comprising a modified osteopontin polypeptide in which an rgd domain is inactivated; and a pharmaceutically acceptable and/or cosmetically acceptable excipient, carrier or diluent. The invention further provides methods of stimulating hair growth in a mammal..
Folicum Ab
01/15/15
20150018251

Protein chips, preparation and use thereof


The present invention relates to the field of medicine, in particular of research and diagnosis. It relates more particularly to a novel tool for detecting antibodies in a biological sample originating from a mammal.
Universite Claude Bernard Lyon 1
01/15/15
20150017724

Method for guiding the derivation of endothelial cells from human pluripotent stem cells employing two-dimensional, feeder-free differentiation


This invention relates, e.g., to a method for differentiating mammalian (e.g., human) pluripotent stem cells (pscs) into endothelial cells (ecs) in vitro, by plating a single-cell suspension of pscs onto a suitable surface such as type iv collagen and culturing the cells with vegf after which ecs can be harvested. A preferred embodiment of the method first cultures the cells without vegf and then sequentially cultures the cells with vegf.
The Johns Hopkins University
01/15/15
20150017676

Capsules containing mammalian cells


A capsule containing at least one mammalian cell, includes a liquid core, and at least one external envelope totally encapsulating the liquid core at its periphery, the external envelope including at least one gelled polyelectrolyte and/or a stiffened biopolymer and being able to retain the liquid core when the capsule is immersed in a gas. The present invention further relates to the method for preparing such a capsule, to a method for screening cosmetic active ingredients as well as a culture method using such capsules..
Capsum
01/15/15
20150017663

Identification of antitumor compounds using placenta


Provided herein are methods of evaluating potential antitumor compounds, and thereby identifying antitumor compounds, using placenta or a portion thereof and tumor cells, and compositions for accomplishing the same. In one embodiment, provided herein is a method of determining whether a potential antitumor compound is effective against a plurality of tumor cells, comprising introducing a plurality of tumor cells to, e.g., into or onto, a mammalian placenta or portion thereof; contacting said plurality of tumor cells for a period of time with said antitumor compound; and determining whether said antitumor compound is effective against said tumor cells, wherein said antitumor compound is effective against said tumor cells if said antitumor compound over said period of time reduces the number of said tumor cells or reduces the growth rate of said tumor cells..
Anthrogenesis Corporation
01/15/15
20150017661

Methods for detecting 5t4-positive circulating tumor cells and methods of diagnosis of 5t4-positive cancer in a mammalian subject


Methods are provided for detecting 5t4-positive circulating tumor cells in a mammalian subject. Methods of diagnosing 5t4-positive cancer in a mammalian subject are provided.
Epic Sciences, Inc.
01/15/15
20150017267

Treatment of inflammatory disorders in non-human mammals


The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents.. .
The Regents Of The University Of California
01/15/15
20150017254

Method for treatment of cardiovascular disorders


Methods for treating a cardiovascular disorder comprising concomitant administration of one or more extracellular matrix (ecm) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. In a preferred embodiment, the ecm based compositions include an ecm material derived from a mammalian source..
Cormatrix Cardiovascular, Inc.
01/15/15
20150017249

Sustained-release formulations of topiramate


Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile.
Supernus Pharmaceuticals, Inc.
01/15/15
20150017199

Cholera toxin chimera and its use as a staph vaccine


The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from s.
Boise State University
01/15/15
20150017145

Pharmaceutical kits comprising mesenchymal stem cells


A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration of tendons in competitive mammals, such as the superficial digital flexor tendon of the horse..
Recellerate, Inc.
01/15/15
20150017129

Preservation of the biological activity of undenatured type ii collagen


The instant invention is the storage of type ii collagen containing tissue in carbonated water. Such type ii collagen is useful for alleviating the symptoms of arthritis in mammals as well as the treatment of arthritis in mammals.
01/08/15
20150011837

Sheathed optical fiber


An optical device for illuminating the vasculature of a mammal using ultraviolet, visible, and/or infrared light is described. The optical device includes an optical fiber encased in a biocompatible sheath, and is dimensioned to lie within an intravascular catheter.
Uvl Blood Labs, Inc.
01/08/15
20150011649

Methods of treating infectious diseases


The present invention provides methods of treating a human or other mammal infected with a parasitic microorganism by administering an effective amount in unit dosage form of a c8-c16-alpha, beta-unsaturated aliphatic aldehyde, such as trans-2-dodecenal, to the human or other mammal. The parasitic microorganisms may include trypanosomes, bacteria, fungi and nematodes..
Slippery Rock University Foundation, Inc.
01/08/15
20150011629

Bioactive depside and anthocyanin compounds, compositions, and methods of use


Methods for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside or an anthocyanin are provided. More particularly, a method for modulating the level of a chemokine in a cell by administering to a cell an effective amount of a depside having the structure of formula (iv): formula (iv) wherein r is selected from h or ch3 or an anthocyanin selected from cyanidin 3-glucoside, delphinidin 3-glucoside, or combinations thereof, or an enantiomer, optical isomer, diastereomer, n-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof is provided.
The Trustees Of Columbia University In The City Of New York
01/08/15
20150011612

Rnai modulation of rsv and therapeutic uses thereof


The present invention is based on the in vivo demonstration that rsv can be inhibited through intranasal administration of irna agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated concurrently.
Alnylam Pharmaceuticals, Inc.
01/08/15
20150011603

Etomidate analogues that do not inhibit adrenocortical steroid synthesis


The invention is directed to compounds according to formula (i): where r1 is l1c(o)ot or l1c(o)ol2c(o)ot; r2 is a substituted or unsubstituted c1-c10 alkyl, c2-c10 alkenyl, or c2-c10 alkynyl, or r1; n is an integer from 0 to 5; each r3 is independently halogen or r2; r4 and r5 are independently h, halogen, cn or cf3; l1 and l2 are each independently a bond, a substituted or unsubstituted c1-c10 alkylene, c2-c10 alkenylene, or c2-c10 alkynylene; and t is h, a substituted or unsubstituted c1-c10 alkyl, c2-c10 alkenyl, or c2-c10 alkynyl, nitrophenol, or cyclopropyl. The invention is also directed to a pharmaceutical composition comprising a compound according to formula (i) and a pharmaceutically acceptable carrier, and to methods for providing anesthesia in mammals by administering such a pharmaceutical composition..
The Brigham And Women's Hospital, Inc.
01/08/15
20150011568

Famciclovir for the treatment of recurrent herpes labialis using a one-day treatment


A method for the treatment of recurrent herpes labialis in mammals, including humans, which method comprises administering to the mammal in need of such treatment, and effective amount of penciclovir or famciclovir, or a pharmaceutically acceptable salt thereof for a period of one day.. .
01/08/15
20150011542

Methods of treating adverse intestinal effects of non-steroidal anti-inflammatory drugs


Methods of treating adverse intestinal effects of a non-steroidal anti-inflammatory drugs (nsaid) in a subject by administering to the subject a therapeutically effective amount of a selective bacterial beta-glucuronidase inhibitor. The adverse intestinal effects to be treated include the formation or growth of an intestinal ulcer, increased intestinal permeability, the loss of intestinal villi, bleeding of the intestinal mucosa, and an increased intestinal inflammatory response.
University Of Connecticut
01/08/15
20150011465

Peptoid oligomers, pharmaceutical compositions and methods of using the same


The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics..
01/08/15
20150011461

Heteroaryl pyridone and aza-pyridone amide compounds


Heteroaryl pyridone and aza-pyridone amide compounds of formula i are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting btk, and for treating cancer and immune disorders such as inflammation mediated by btk. Methods of using compounds of formula i for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
Genentech, Inc.
01/08/15
20150010999

Synthetic attachment medium for cell culture


An aqueous cell culture medium composition includes an aqueous cell culture solution configured to support the culture of mammalian cells. The composition further includes a synthetic polymer conjugated to a polypeptide dissolved in the aqueous cell culture solution.
Corning Incorporated
01/08/15
20150010927

Detecting latent tuberculosis infections


This document provides methods and materials related to identifying mammals having a ltbi. For example, methods and materials for using elispot assays to identify mammals (e.g., humans) having a ltbi are provided..
Mayo Foundation For Medical Education And Research
01/08/15
20150010672

Slowly fermentable soluble dietary fiber


The embodiments described herein provide a method for improving bowel health by increasing short chain fatty acid concentration in the colon of a mammal including administering to the mammal a composition having from about 0.1 grams to about 50 grams of a treated bran product. After administration, the treated bran product results in an increased short chain fatty acid production during fermentation in the colon as compared to untreated bran fermented in the colon..
Purdue Research Foundation
01/08/15
20150010597

Compositions and methods for vaccinating against hsv-2


This invention relates to therapeutic polynucleotide compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The polynucleotide compositions are particularly effective for protecting mammals from herpes simplex virus (hsv), such as hsv gd2, vp11/12, and vp13/14 polypeptides..
The University Of Washington
01/08/15
20150010596

Compositions and methods for vaccinating against hsv-2


This invention relates to therapeutic compositions and methods for systemic immune activation which are effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in mammals. The methods are particularly effective for protecting mammals from herpes simplex virus..
The University Of Washington
01/08/15
20150010592

Capsular gram-positive bacteria bioconjugate vaccines


The present invention encompasses a novel s. Aureus bioconjugate vaccine.
Glycovaxyn Ag
01/08/15
20150010558

Compositions and methods for treating coagulation related disorders


Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (tf) to form a complex in which factor x or factor ix binding to the complex is inhibited and the administration is sufficient to prevent or treat the sepsis in the mammal.
Genentech, Inc.
01/08/15
20150010557

Propylene glycol compositions for intranasal administration of active agents to the central nervous system


Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein.
Janssen Biotech, Inc.
01/08/15
20150010530

Modified vitamin k-dependent polypeptides


The invention provides vitamin k-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals.
Regents Of The University Of Minnesota
01/08/15
20150010515

Mammalian neural plate border stem cells capable of forming neural tube and neural crest cell lineages including central and peripheral neurons


The present invention relates to a method for producing mammalian neural plate border stem cells (npbscs), comprising: (a) differentiation of mammalian pluripotent stem cells by (a-i) culturing mammalian pluripotent stem cells in pluripotent stem cell medium for about 24 to about 96 hours, wherein the pluripotent stem cell medium comprises: (i) an inhibitor of the activin/tgf-β signalling pathway; (ii) an inhibitor of the bmp signalling pathway; (iii) an activator of the canonical wnt signalling pathway; and (iv) an activator of the hedgehog signalling pathway; subsequently (a-ii) culturing the cells obtained in step (a-i) for about 24 to about 96 hours in a neural medium, wherein the neural medium comprises: (i) an inhibitor of the activin/tgf-β signalling pathway; (ii) an inhibitor of the bmp signalling pathway; (iii) an activator of the canonical wnt signalling pathway; and (iv) an activator of the hedgehog signalling pathway; subsequently (a-iii) culturing the cells obtained in step (a-ii) for about 24 to about 96 hours in a neural medium, wherein the neural medium comprises: (i) an activator of the canonical wnt signalling pathway; (ii) an activator of the hedgehog signalling pathway; and (iii) an inhibitor of oxidation; and (b) plating the obtained differentiated mammalian pluripotent stem cells in npbscs expansion medium, wherein the npbscs expansion medium comprises (i) an activator of the canonical wnt signalling pathway; (ii) an activator of the hedgehog signalling pathway; and (iii) an inhibitor of oxidation; and expanding the cells in the npbscs expansion medium for about 24 to about 96 hours; (c) splitting the cells obtained in (b) and further expanding the cells in the npbscs expansion medium; and (d) repeating step (c) at least two times. The present invention further relates to neural plate border stem cells obtainable by the method of the invention and the use of the cells of the invention in medicine..
Max- Planck-gesellschaft Zur Förderung Der Wissenschaften E.v.
01/08/15
20150010471

Temporary embolization using inverse thermosensitive polymers


One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an mri-visible compound..
Genzyme Corporation
01/08/15
20150007814

Conversion of nitrogen dioxide (no2) to nitric oxide (no)


A nitric oxide delivery system, which includes a gas bottle having nitrogen dioxide in air, converts nitrogen dioxide to nitric oxide and employs a surface-active material, such as silica gel, coated with an aqueous solution of antioxidant, such as ascorbic acid. A nitric oxide delivery system may be used to generate therapeutic gas including nitric oxide for use in delivering the therapeutic gas to a mammal..
Geno Llc
01/01/15
20150007357

Use of humanized mice to determine toxicity


The invention is directed to a method of determining whether an agent causes immune toxicity in a human comprising administering the agent to a non-human mammal that has been engrafted with human hematopoietic stem cells (hscs) and administered one or more human cytokines; and determining whether the agent causes immune toxicity in the non-human mammal. If the agent causes immune toxicity in the non-human mammal then the agent causes toxicity in a human.
Massachusetts Institute Of Technology
01/01/15
20150005869

Kink resistant graft devices and related systems and methods


A graft device including a conduit and a fiber matrix surrounding the conduit for a mammalian patient is disclosed. The graft device further includes a kink resisting element such that the graft device is configured to reduce kinking.
Neograft Technologies, Inc.
01/01/15
20150005692

Method for the treatment of mammalian skin tissues via pulse irradiation in the presence of a photoactive compound


A method of treating mammalian skin tissues for causing a predetermined physiological change in the mammalian skin tissues. A treatment composition of matter is applied onto the mammalian skin.
01/01/15
20150005691

Thermal treatment of a pilosebaceous unit with metal nanoparticles in surfactant containing solutions


Treatment of skin tissue with photoactive materials and light, such as nanoparticles and formulations which are useful for cosmetic, diagnostic and therapeutic applications to mammals such as humans. In particular, embodiments of thermal treatment of a pilosebaceous unit with metal nanoparticles in surfactant containing solutions are disclosed..
Sienna Labs, Inc.
01/01/15
20150005534

Cells and methods for producing lutein


Provided herein are recombinant cells (e.g., recombinant bacteria or plant, insect, mammalian, and yeast cells) containing a nucleic acid encoding a cyp97a protein or a nucleic acid encoding a cyp97b protein; a nucleic acid encoding a cyp97c protein; a nucleic acid encoding a geranylgeranyl pyrophosphate synthase protein; a nucleic acid encoding a phytoene synthase protein; a nucleic acid encoding a phytoene desaturase protein; a nucleic acid encoding a lycopene β-cyclase protein; and a nucleic acid encoding a lycopene ε-cyclase protein. Also provided are methods of producing lutein that include culturing these recombinant cells (e.g., recombinant bacteria and yeast cells), and methods of generating these recombinant cells (e.g., recombinant bacteria and yeast cells).
The Research Foundation Of The City University Of New York
01/01/15
20150005499

Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds


Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or typanosoma cruzi infection in a mammal.. .
Array Biopharma Inc.
01/01/15
20150005381

Method for modulating stem cell growth


In one embodiment, provided is a composition including a prostaglandin compound for modulating stem cell proliferation and/or differentiation in a mammalian subject. In another embodiment, the instant application is directed to a composition which includes a prostaglandin compound for modulating proliferation and/or differentiation of stem cells of a mammalian subject, in which the stem cells are contacted directly or indirectly with the composition of the invention..
Sucampo Ag
01/01/15
20150005369

Methods of gene delivery using capsid-modified raav expression systems


Disclosed are methods of gene delivery using capsid-modified recombinant adeno-associated viral (raav) vectors. Exemplary methods are provided employing vectors that have altered affinity for heparin or heparin sulfate, as well as vectors, expression systems, and raav virions that lack functional vp2 protein expression, but are nevertheless, fully virulent.
University Of Florida Research Foundation, Inc.
01/01/15
20150005337

Transdermal delivery of systemically active central nervous system drugs


The invention relates to a transdermal or transmucosal non-occlusive, semi-solid pharmaceutical formulation that includes at least one systemically active agent that acts on the central nervous system (cns) of a mammal; and a permeation enhancing solvent system present in an amount sufficient to solubilize the at least one active ingredient. The permeation enhancing solvent system includes a pharmaceutically acceptable monoalkyl ether of diethylene glycol; a pharmaceutically acceptable glycol; preferably also a fatty alcohol and or a fatty acid; and a mixture of a c2 to c4 alcohol and water so that the permeation enhancing solvent system (a) inhibits crystallization of the at least one active ingredient on a skin or mucosal surface of a mammal, (b) reduces or prevents transfer of the formulation to clothing or to another being, (c) modulates biodistribution of the at least one active agent within different layers of skin, (d) facilitates absorption of the at least one active agent by a skin or a mucosal surface of a mammal, or (e) provides a combination of one or more of (a) through (d)..
Antares Pharma Ipl Ag
01/01/15
20150005324

Famciclovir for the treatment of recurrent herpes labialis using a one-day treatment


A method for the treatment of recurrent herpes labialis in mammals, including humans, which method comprises administering to the mammal in need of such treatment, an effective amount of penciclovir or famciclovir, or a pharmaceutically acceptable salt thereof for a period of one day.. .
01/01/15
20150005291

Compositions for increasing hair growth


Cosmetic skin and hair care compositions for enhancing the growth and appearance of mammalian hair in an individual are provided, which compositions comprise a dose of an l-type calcium channel blocker effective to promote anagen phase of the hair cycle. As shown herein, anagen phase promotion can result in more rapid hair growth..
The Board Of Trustees Of The Leland Stanford Junior University
01/01/15
20150005256

Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex


The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a dna binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a dna construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the dna binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.. .
Intrexon Corporation
01/01/15
20150005246

Use of jasmonate to treat bladder dysfunction


A formulation or composition contractility comprising jasmonate for modulating bladder and/or treating bladder dysfunction, particularly an overactive bladder in a mammal, particularly a human and use of jasmonate for treating bladder dysfunction is provided.. .
01/01/15
20150005236

Use of beta-nerve growth factor for inducing ovulation in mammals


The use of beta-nerve growth factor for inducing ovulation in a mammal. A pharmaceutical or veterinary composition for inducing ovulation in a mammal comprises beta-nerve growth factor in a pharmaceutically acceptable carrier..
Institut National De La Recherche Agronomique
01/01/15
20150005231

Halogen-stabilized insulin


An insulin analogue comprises a b-chain polypeptide incorporating a halogenated phenylalanine at position b24, b25 or b26. The halogenated phenylalanine may be ortho-monofluoro-phenylalanine, ortho-monobromo-phenylalanine, ortho-monochloro-phenylalanine, or para-monochloro-phenylalanine.
Case Western Reserve University
01/01/15
20150005177

Methods of identifying, isolating and using odorant and aroma receptors


Provided here are new methods to identify specific families of mammalian odorant receptors for odorants or aroma, particularly indole and skatole malodors and their use in assays that may be used to discover compounds that modulate (blocking, enhancing, masking or mimicking compounds) their activity. Orphan mouse odorant receptors are identified from olfactory sensory neurons that respond to target compounds.
Firmenich Sa


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.5142

3147

0 - 1 - 75